Clancy J. Clark MD

Hepatobiliary and Pancreatic Surgeon | Data Scientist | Director of HPB Surgery | Opinions are my own and not my employers.

[Clancy J. Clark MD @ClancyClark]

Neoadjuvant GOLP chemo regimen doubles event-free survival in resectable iCCA, 18 vs. 9 months. 🔬 Time to consider preop chemo in patients at high risk of recurrence. 🎯 #Cholangiocarcinoma #HPBSurgery ➡️ https://t.co/pR2pvyb8Ls

[Clancy J. Clark MD @ClancyClark]

⚠️ Subtotal cholecystectomy: BDI rate just 0.3%, but bile leak 13.5% & ERCP needed in 16%. Pivoting strategy is surgical judgment, not defeat. ➡️ https://t.co/d3Z7glAJaz

[Clancy J. Clark MD @ClancyClark]

🎯 ctDNA+ after pancreatic cancer resection = ~80% recurrence risk. But ctDNA negative ≠ safe. Imaging surveillance remains essential. Promising adjunct, not a standalone tool. #PancreaticCancer #HPBSurgery #LiquidBiopsy ➡️ https://t.co/XEyVMa2KNN

[Clancy J. Clark MD @ClancyClark]

@TheNotoriousHPB Non-con CT for Kidney stones...sure. Free air...yeah you'll see it and call a surgeon who will order a contrasted CT. In our business--HPB surgery--non-con CT drastically decreases sensitivity and specificity but still helpful in unique clinical scenarios

[JAMA @JAMA_current]

💬 Viewpoint: Integration of #AI in medicine risks “never skilling” for trainees; deliberate design—such as commit-then-compare, AI coaching, and AI-free zones—is needed to support clinical expertise development.

https://t.co/HeXgOatLUW

[Society of Surgical Oncology @SocSurgOnc]

Join us for our upcoming CGSO Videoconference: Gastric. Featuring live case presentations by CGSO Fellows from Roger Williams Medical Center and Roswell Park, with guest expert Dan Blazer III (Trey), MD, FACS.

Register now:
https://t.co/i9QcFTYT3y

[SSAT @SSATNews]

Join the SSAT for our upcoming Complex GS Fellowship Virtual Grand Rounds Webinar: “GE Junction Cancer”

🗓 Monday, May 11, 2026
🕔 5 PM ET (4 PM CT | 3 PM MT | 2 PM PT)

Register now: https://t.co/0NabH5lBoA
@blondescalpel
@JeyarajahRohan

#SSAT #GrandRounds #SurgicalEducation

[Clancy J. Clark MD @ClancyClark]

🤖 Robotic cholecystectomy use in BMI ≥50 rose from 23%→56% (2020–2024), yet outcomes mirror laparoscopic across all BMI groups. Expertise > technology. 🏥 Patient selection still drives results. #HPBSurgery #RoboticSurgery #JACS ➡️ https://t.co/3XkHi1loNd

[Clancy J. Clark MD @ClancyClark]

Honored to be at #PancreasClub2026 — cutting-edge science on pancreatic cysts, PDAC, and surgical innovation. This is where evidence meets practice. If you have pancreatic disease, this is the community fighting for you.
#HPBSurgery #PancreaticCancer #DDW2026

[Clancy J. Clark MD @ClancyClark]

🙋‍♂️Has anyone incorporated drain CRP into their whipple post-op care pathway? I share my thoughts in a recent Annals of Surgical Oncology editorial ✍️ https://t.co/DmmmnZeEBm

You can read Dr. Baba’s study on using drain CRP here https://t.co/nQmfbytyIC

[Clancy J. Clark MD @ClancyClark]

🤔Trying to wrap my head around this one.

🔥The word is out. It is spreading like wildfire among trainees🔥

OpenEvidence: OpenEvidence Creates the First AI in History to Score a Perfect 100% on the

USMLE https://t.co/zxQXjeNhhh

[SSAT @SSATNews]

Join us for the next SSAT Complex GS Fellowship Grand Rounds Webinar

November 10, 2025 from 5–6 PM ET

Featuring @JeyarajahRohan, @KevinElHayekMD, @blondescalpel, & @mpmartinezs

Register: https://t.co/MPnU6d1eF4

#SSAT #GrandRounds #SurgicalEducation #Surgery

[Annals of Surgery @AnnalsofSurgery]

Nearly 1 in 4 cancer patients reported a disability. They faced higher costs, more transportation barriers, and worse health outcomes compared with nondisabled peers.
https://t.co/qkFNPal0E7

[Clancy J. Clark MD @ClancyClark]

📈 “Textbook Outcomes” have been explored in liver and pancreas surgery helping us understand ideal outcomes 🏆 🥇

How do we use this in the real world? 🤔

Using Data to Inform Preoperative Discussions https://t.co/tWzjU9Klol

[SSAT @SSATNews]

Congratulations to the 2025–2026 SSAT Visiting Grand Round Professorship recipients:

@Sharpknife_Aziz
@UIowa_Surgery
@Dr_Sal_Docimo
@TheNotoriousHPB
@LVHN
@JVelottaMD
@kpnorcal
@USFsurgery

#SSATAwards #VisitingProfessorship #SurgicalEducation #SSAT2025

[Clancy J. Clark MD @ClancyClark]

New pancreatic cancer trial just posted on https://t.co/wSoeXKjDqr A Prospective Observational Cohort Study on Longitudinal Monitoring of ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer https://t.co/v0UjCcFizp

[Clancy J. Clark MD @ClancyClark]

New pancreatic cancer trial just posted on https://t.co/wSoeXKjDqr Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer https://t.co/xd9aGbiBZB

[Clancy J. Clark MD @ClancyClark]

New pancreatic cancer trial just posted on https://t.co/wSoeXKjDqr A Study Comparing Restrictive and Liberal Fluid Therapy During Pancreatecoduodenectomy Surgery https://t.co/JjH9dzmqer

[Clancy J. Clark MD @ClancyClark]

New pancreatic cancer trial just posted on https://t.co/wSoeXKjDqr Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer https://t.co/ZQB6h6d0ch

[Clancy J. Clark MD @ClancyClark]

New pancreatic cancer trial just posted on https://t.co/wSoeXKjDqr A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002) https://t.co/MZZgB6Uodc